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Here we report two new cases of IgA-Lymphoplasmacytic Lymphoma (LPL) with diverse 
clinical presentation and performed a review of the three cohorts of patients with non-IgM 
LPL published in the literature. IgA LPL is rare and affects patients with a mean age at 
diagnosis of 67-year-old, with male predominance. Hyper viscosity related symptoms are 
extremely uncommon in comparison with LPL/WM and reported in unique cases. 
Extramedullary involvement includes lymph node disease (6/14, 42%) and rarely 
splenomegaly (3 cases, 21%). Associated amyloid deposition has been found in 21% of the 
cases. Histopathological features in the bone marrow if IgA-LPL are equivalent to IgM-
LPL/WM. IgA LPL are positive for MYD88L265P mutation in 83% of the cases (10/12 
cases). 6 q deletion is rarely found. In conclusion, the available evidence about the biological 
features of IgA-LPL supports the inclusion of these cases in the lymphoplasmacytic 
lymphoma spectrum. This is relevant for therapeutic reasons, mainly due to the availability of 
novel highly effective regimens for the treatment of LPL/WM. 
 
Lymphoplasmacytic Lymphoma (LPL)/ Waldestrom Macroglobulinemia is a neoplasm of 
small B lymphocytes, plasmacytoid lymphocytes and plasma cells, usually involving the 
bone marrow and sometimes lymph node and spleen
1
 with an associated IgM monoclonal 
component
2
. MYD88L265P somatic mutation is the driver mutation in most cases
3-6
. Patients 
with IgG or IgA monoclonal proteins and those with non-secretory LPL exist and show 
clinical and pathological heterogeneity
7,8
.  
Here we describe two cases of IgA LPL diagnosed and treated in our institution. These two 
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Both patients were elderly men (71 and 75-year-old). Patient 1 presented with constitutional 
symptoms. On CT scan retroperitoneal pathological lymph nodes were identified.  Case 2 
presented with asthenia and bone pain. After CT no pathological lymph nodes were identified. 
Neither of the patients had hepatosplenomegaly, CNS involvement, bone lesions nor hyper 
viscosity related symptoms at diagnosis. Both patients had anemia, elevated β2-
microglobulin, Bence-Jones proteinuria and IgA positive M component of 1.54 g/dL and 5.82 
g/dL, respectively. Case 1 had, by FCM a 0.98% population of clonal B cells with kappa light 
chain restriction in the peripheral blood without increased lymphocytes, plasma cells, nor 
atypical cells in the PB smear.  
 
In both cases bone marrow core biopsy established the diagnosis of LPL, based on the 
unequivocal infiltration of the marrow space (Figure). Bone marrow aspirate in case 1 
showed 18.5% lymphocytes (4.5% clonal by FCM)  and 2% plasma cells. Case 2 had 25% 
lymphocytes in the BM aspirate (13% clonal by FCM) and 3.5% plasma cells. Dutcher bodies 
were not identified, and mast cells were within normal limits. Case 2 had increased 
histiocytes in the marrow core biopsy. Case 1 had associated AL-k amyloid deposits in both 
bone marrow and retroperitoneal lymph node tissues. Both cases showed a clonal B cell 
population with plasma cell differentiation and IgA expression in the lymphoid and plasma 
cell population as demonstrated by IHC. Molecular testing demonstrated the presence of 
MYD88L265P mutation by Allele Specific-PCR in the bone marrow clot material from both 
cases. In both cases FISH was performed in the bone marrow aspirate and was found positive 
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Case number 1 was treated with immunochemotherapy with Rituximab, Bortezomib and 
Dexamethasone. After 6 cycles the patient achieved partial response. The second patient was 
treated with Rituximab, cyclophosphamide and dexamethasone. After 2 cycles the patient 
developed a cutaneous rash and hyper viscosity related symptoms. A second line treatment 
with Ibrutinib is now ongoing. 
 
We reviewed the clinical, morphological, phenotypical and molecular features in comparison 
with the cases described in the three larger cohorts of patients with non-IgM LPL so far 
published
7,8,10
 (Table). Including the two cases here reported IgA-LPL affects patients with a 
mean age at diagnosis of 67-year-old (range 51-80) and male predominance (9 out of 14 
cases). Mean serum IgA M component was 3 g/dL (0.74-5.75 g/dL). 42% of the cases 
presented with anemia and with B symptoms. Hyper viscosity related symptoms such as 




Extramedullary involvement in these patients usually includes lymphadenopathy (6/14, 42%) 
and rarely splenomegaly (3 cases, 21%). CNS involvement by IgA-LPL has not been reported. 
Associated amyloid deposition has been described in two previously published cases (3 out of 
14 cases, 21%, including our case number 1).  
 
Histopathological features in the bone marrow of IgA-LPL are equivalent to IgM-LPL/WM, 
including paratrabecular and interstitial clonal B cell infiltrates with plasma cell 
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Molecular features of IgA-LPL include the frequent detection of MYD88L265P mutation. 
Including our two cases, IgA LPL are reported to be positive in 83% of the cases (10/12 cases 
7,8,10
). The identification of MYD88L265P mutation in IgA-LPL aids in the differential 
diagnosis with multiple myeloma and marginal zone lymphoma, since it is never found in 





The prevalence of other genetic features found in WM such as 6q deletion is poorly defined 
in the non-IgM LPL group of cases 
9
. 6q deletion in WM has been found to be associated 
with features of poor prognosis
14,15
 and upregulation of BCR pathway
16
. The clinical 
significance of this alteration in IgA-LPL is however not well stablished.  
 
In conclusion here we report two cases of IgA-LPL with diverse clinical presentation. Bone 
marrow histopathological findings and demonstration of MYD88L265P mutation were 
essential for the diagnosis. The available evidence about the biological features of IgA-LPL 
supports the inclusion of these cases in the lymphoplasmacytic lymphoma spectrum. This is 
critical for therapeutic reasons, mainly due to the availability of novel highly effective 
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Figure. Case 1. IgA lymphoplasmacytic lymphoma, involving bone marrow and lymph 
nodes with amyloid deposits. (A,B, H&E). The bone marrow core biopsy shows 
paratrabecular and interstitial infiltration of small lymphocytes some with plasmacytoid 
features and plasma cells (20% of marrow cellularity). Interstitial deposits of amyloid were 
also identified.  IHC shows positivity for CD20 (C), CD138 (D) and IgA (E). There was 
kappa light chain restriction (F). The pink amorphous material was positive for P protein (G). 
HE from the retroperitoneal LN biopsy discloses the same combination of lymphoid and 
plasmacytoid infiltrates with amyloid material, positive with Congo red staining under 
polarized light (H, I). Case 2. IgA kappa lymphoplasmacytic lymphoma involving bone 
marrow (J, K, H&E). The bone marrow core biopsy shows a diffuse-solid interstitial 
infiltrate of small lymphocytes, plasmacytoid lymphocytes and plasma cells (80% of the 
marrow cellularity).  IHC shows positivity for CD20 (L), CD138 (M) and IgA (N). There was 
kappa light chain restriction (O). 
 
Table. Clinicopathological features of patients with IgA Lymphoplasmacytic Lymphoma.  
A summary of the clinical and pathologic features of the IgA LPL cases described in the three 
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                                Cao et al. Leukemia & Lymphoma 2016 King et al. AJCP, 2016 Tursz et al. Am J Med, 1977 Urquieta Lam et al. TOTAL
n 8 2 2 2 14 
Clinical features
Age (years) 65 (51-80) 62 (54-70) 69 (58-80) 73 (71-75) 67 (51-80)
Male (n, %) 5 (62) 2 (100) 0 (0) 2 (100) 9 (64.28)
Female (n, %) 3 (38) 0 (0) 2 (100) 0 (0) 5 (35.72)
Serum IgA (in mg/dL; mean, range) 2475 (747-5260) 1750 (1000-2500) 4550 (3800-5300) 3575 (1400-5750) 3087 (747-5750)
Anemia (n, %) 2 (16%) 2 (100) —- 2 (100) 6 (42)
B symptoms (n, %) 5 (62) —- —- 1 (50) 6 (42.85)
Visual impairment (n, %) 0 (0) 0 (0) —- 0 (0) 0 (0)
Hyperviscosity (n, %) 0 (0) 0 (0) 0 (0) 1 (50) 1 (7)
Amyloidosis (n, %) 1 (12.5) 1 (50) —- 1 (50) 3 (21.42)
Neuropathy (n, %) 1 (12.5) 0 (0) —- 1 (50) 2 (14.29)
Bence-Jones proteinuria (n, %)  — —- 0 (0) 2 (100) 2 (14.29)
Pathological features
BM involvement (n, %) 8 (100) 2 (100) 2 (100) 2 (100) 14 (100)
Extramedullary involvement (n, %)* 6 (75) 0 (0) 0 (0) 1 (50) 7 (50)
Splenomegaly (n, %) 1 (12.5) 0 (0) 2 (100) 0 (0) 3 (21.42)
Hepatomegaly (n, %) 0 (0) 0 (0) 1 (50) 0 (0) 1 (7.14)
Lymphadenopaty (n, %) 5 (62.5) 0 (0) 0 (0) 1 (50) 6 (42.85)
CNS involvement (n, %) 0 (0) 0 (0) —- 0 (0) 0 (0)
Molecular feaures
FISH/Karyotype 6qdel (%) 0/8 (0) 0 (0) ** —- 1/2 (50) 1
MYD88 L265P mutation, positive (%) 6 (75) 2 (100) —- 2 (100) 10 (83)
Therapy
Treatment *** 8 (100) 1 (50) 1 (50) 2 (100) 12 (92)
Watch and wait 0 1 (50) 0 (0) 0 (0) 1 (8)
* 5 cases with LN involvement and 1 case with renal and nasopharinx involvement.
** Karyotype performed on 18 of 23 lymphoma cases
*** R+/- diverse chemotherapy regimens +/- ASCT
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